Psilocybin Meets the Bar: Compass Pathways' Dual Phase 3 Wins Signal FDA Filing Ahead

Compass Pathways’ COMP360 psilocybin therapy succeeded in two Phase 3 trials for treatment-resistant depression. Fast relief, lasting effects, and good safety profile – could be the first psilocybin medicine approved by FDA.